NDA 021540 · Pharmacia
Caduet
Amlodipine Besylate, Atorvastatin Calcium · Oral
Last checked: Nov 20, 2026Latest source record: Nov 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Jan 30, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
656
178 Phase 3, 22 recruiting
FAERS reports
4,091
2,658 serious, 358 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 30, 2026.
CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. CADUET is a combination of amlodipine besylate, a calcium channel blocker, and atorvastatin calcium, a HMG-CoA-reductase inhibitor (statin), indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate ( 1 ). Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Amlodipine is indicated for the treatment of Coronary Artery Disease ( 1 ). Atorvastatin is indicated ( 1 ): • To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. • As an adjunct to diet to reduce low-density lipoprotein (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia. • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Amlodipine Hypertension Amlodipine is indicated for the treatment of hypertension,...
Mechanism: CADUET is a combination of two drugs, a dihydropyridine calcium channel blocker (amlodipine) and an HMG-CoA reductase inhibitor (atorvastatin). The amlodipine component of CADUET inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The atorvastatin component of CADUET is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Amlodipine Amlodipine binds to both dihydropyridine and nondihydropyridine binding...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
11 products under this application
- CADUET · AMLODIPINE BESYLATE EQ 2.5MG BASE; ATORVASTATIN CALCIUM EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
- CADUET · AMLODIPINE BESYLATE EQ 10MG BASE; ATORVASTATIN CALCIUM EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
- CADUET · AMLODIPINE BESYLATE EQ 10MG BASE; ATORVASTATIN CALCIUM EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
- CADUET · AMLODIPINE BESYLATE EQ 2.5MG BASE; ATORVASTATIN CALCIUM EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
- CADUET · AMLODIPINE BESYLATE EQ 5MG BASE; ATORVASTATIN CALCIUM EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
- CADUET · AMLODIPINE BESYLATE EQ 5MG BASE; ATORVASTATIN CALCIUM EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
- CADUET · AMLODIPINE BESYLATE EQ 10MG BASE; ATORVASTATIN CALCIUM EQ 80MG BASE · TABLET, ORAL · Prescription · TE AB
- CADUET · AMLODIPINE BESYLATE EQ 10MG BASE; ATORVASTATIN CALCIUM EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
- CADUET · AMLODIPINE BESYLATE EQ 5MG BASE; ATORVASTATIN CALCIUM EQ 80MG BASE · TABLET, ORAL · Prescription · TE AB
- CADUET · AMLODIPINE BESYLATE EQ 2.5MG BASE; ATORVASTATIN CALCIUM EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
- CADUET · AMLODIPINE BESYLATE EQ 5MG BASE; ATORVASTATIN CALCIUM EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Amlodipine" as an intervention, any sponsor and status, largest first.
- China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)Pivotal-lookingRecruiting
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT04974138 · 32,000 participants (planned) · Start Aug 22, 2024 · Primary completion Jun 30, 2030
Drug: Amlodipine besylate; Amlodipine besylate and folic acid and 2 more · For: Hypertension; MTHFR 677 CC or CT Genotype; Elevated Plasma Homocysteine (Hcy≥10µmol/L) and 1 more
Sites: Bengbu, China; Bozhou, China; Chizhou, China · 20 sites in all
- China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT GenotypePivotal-lookingRecruiting
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT04974151 · 24,000 participants (planned) · Start Aug 22, 2024 · Primary completion Jun 30, 2029
Drug: Amlodipine besylate; Amlodipine besylate And Folic Acid and 4 more · For: Hypertension; MTHFR 677 TT Genotype
Sites: Bengbu, China; Bozhou, China; Chizhou, China · 20 sites in all
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential HypertensionPivotal-lookingCompleted
Oslo University HospitalAcademic, hospital or other
NCT06395194 · 15,313 participants · Start Sep 27, 1997 · Primary completion Sep 5, 2003
Drug: Cardiac outcomes on treatment with valsartan; Cardiac outcomes on treatment with amlodipine · For: Essential Hypertension
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVDPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT05169021 · 15,000 participants (planned) · Start Dec 31, 2021 · Primary completion Dec 31, 2024
Drug: Amlodipine folic acid 5.8mg+intensive antihypertensive therapy; Amlodipine folic acid 5.8mg+standard antihypertensive therapy and 2 more · For: Cerebral Small Vessel Diseases; Stroke
Sites: Beijing, China
- Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT01011660 · 13,542 participants (planned) · Start Oct 2007 · Primary completion Aug 2012
Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin · For: Essential Hypertension
Sites: Beijing, China
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionPivotal-lookingTerminated
NovartisNovartis (NVS)
NCT00170950 · 11,506 participants · Start Oct 2003 · Primary completion Jan 2008
Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 and 4 more · For: Hypertension
Sites: East Hanover, New Jersey; Denmark, Denmark; Finland, Finland · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness184
- drug ineffective178
- nausea178
- fatigue175
- malaise163
- pain148
- dyspnoea146
- death144
- headache133
- hypertension133
- asthenia126
- diarrhoea124
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 52 |
| 2006 | 102 |
| 2007 | 193 |
| 2008 | 169 |
| 2009 | 217 |
| 2010 | 622 |
| 2011 | 291 |
| 2012 | 356 |
| 2013 | 275 |
| 2014 | 250 |
| 2015 | 226 |
| 2016 | 176 |
| 2017 | 161 |
| 2018 | 129 |
| 2019 | 177 |
| 2020 | 199 |
| 2021 | 105 |
| 2022 | 98 |
| 2023 | 89 |
| 2024 | 79 |
| 2025 | 64 |
| 2026 | 57 |
Recalls
2 FDA enforcement reports for this application.
Feb 5, 2020 · Class II · Terminated
Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.
Feb 5, 2020 · Class II · Terminated
Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Caduet (Amlodipine/Atorvastatin)
2024 spending
$395K
Beneficiaries
68
248 claims
Per beneficiary
$5,804
$21.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,144,281 |
| 2021 | $1,444,023 |
| 2022 | $926,526 |
| 2023 | $385,568 |
| 2024 | $394,684 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Xie M, Tang T, Liang H · Clin Cardiol 2023 · Systematic Review, Network Meta-Analysis
- Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis.
Yin J, Mei Z, Shi S, et al. · Arch Gynecol Obstet 2022 · Meta-Analysis, Systematic Review
- Amlodipine pharmacokinetics in healthy volunteers.
Williams DM, Cubeddu LX · J Clin Pharmacol 1988 · Clinical Trial, Randomized Controlled Trial
- Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
Jin X, Kim MH, Han KH, et al. · J Clin Hypertens (Greenwich) 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Amlodipine reduces blood pressure during dynamic resistance exercise in hypertensive patients.
Souza DR, Gomides RS, Costa LA, et al. · Scand J Med Sci Sports 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A comparison of amlodipine with enalapril in the treatment of moderate/severe hypertension.
Fowler G, Webster J, Lyons D, et al. · Br J Clin Pharmacol 1993 · Clinical Trial, Comparative Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.